1. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance
- Author
-
Keiryn L. Bennett, Stephan N. Wagner, Leon Grinman, Rajasekharan Somasundaram, Harry Choi, Gao Zhang, Richard A. Scolyer, Mizuho Fukunaga-Kalabis, Michael A. Davies, Lynn M. Schuchter, Keith T. Flaherty, Rufus Hards, Lawrence Wu, Denitsa Hristova, Michela Perego, Jennifer A. Wargo, Zhi Wei, Georgios Karanikas, Margarita Maurer, Meenhard Herlyn, Brian J. Czerniecki, Klemens Rappersberger, Manashree Damle, Marilda Beqiri, Laura Gross, Tian Tian, Kanika Garg, Courtney Ellingsworth, Margaret C. Dunagin, Roland Lang, Clemens Krepler, Verena Bauer-Pohl, Helmut Schaider, Ian R. Watson, Marius Mayerhöfer, Qin Liu, Josef Koller, Jie Zhang, Arjun Raj, Guo Chen, Christine Wagner, Johannes Griss, Xiaowei Xu, Brian J. Gavin, Felix Weihsengruber, Christine Hafner, Courtney W. Hudgens, Dorothee Herlyn, Georgina V. Long, Nathalie Scholler, Michael T. Tetzlaff, Ahmad Jalili, and Dennie T. Frederick
- Subjects
0301 basic medicine ,Proto-Oncogene Proteins B-raf ,Skin Neoplasms ,Paclitaxel ,Cell Survival ,medicine.medical_treatment ,Science ,General Physics and Astronomy ,Antineoplastic Agents ,Pilot Projects ,Drug resistance ,In Vitro Techniques ,Antibodies, Monoclonal, Humanized ,General Biochemistry, Genetics and Molecular Biology ,Article ,03 medical and health sciences ,Lymphocytes, Tumor-Infiltrating ,medicine ,Tumor Microenvironment ,Neoplasm ,Humans ,Receptor, Fibroblast Growth Factor, Type 3 ,Insulin-Like Growth Factor I ,lcsh:Science ,Melanoma ,Protein Kinase Inhibitors ,CD20 ,Tumor microenvironment ,B-Lymphocytes ,Multidisciplinary ,biology ,Growth factor ,Antibodies, Monoclonal ,General Chemistry ,medicine.disease ,3. Good health ,030104 developmental biology ,Drug Resistance, Neoplasm ,Monoclonal ,Immunology ,biology.protein ,lcsh:Q ,Fibroblast Growth Factor 2 ,Antibody ,Cisplatin - Abstract
In melanoma, therapies with inhibitors to oncogenic BRAFV600E are highly effective but responses are often short-lived due to the emergence of drug-resistant tumor subpopulations. We describe here a mechanism of acquired drug resistance through the tumor microenvironment, which is mediated by human tumor-associated B cells. Human melanoma cells constitutively produce the growth factor FGF-2, which activates tumor-infiltrating B cells to produce the growth factor IGF-1. B-cell-derived IGF-1 is critical for resistance of melanomas to BRAF and MEK inhibitors due to emergence of heterogeneous subpopulations and activation of FGFR-3. Consistently, resistance of melanomas to BRAF and/or MEK inhibitors is associated with increased CD20 and IGF-1 transcript levels in tumors and IGF-1 expression in tumor-associated B cells. Furthermore, first clinical data from a pilot trial in therapy-resistant metastatic melanoma patients show anti-tumor activity through B-cell depletion by anti-CD20 antibody. Our findings establish a mechanism of acquired therapy resistance through tumor-associated B cells with important clinical implications., Resistance to BRAFV600E inhibitors often occurs in melanoma patients. Here, the authors describe a potential mechanism of acquired drug resistance mediated by tumor-associated B cells-derived IGF-1.
- Published
- 2017